Labcorp Holdings Inc. (LH)
Labcorp is a global healthcare giant that runs the massive network of laboratories and diagnostic services used by doctors to test your blood and samples.
Is Labcorp Holdings Inc. a good stock for a UK beginner?
The honest version: Labcorp is a global healthcare giant that runs the massive network of laboratories and diagnostic services used by doctors to test your blood and samples.
Over about 2 years to 2026-07-31. This is the share price only - reinvesting the dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Dominance in the growing personalised medicine market
Significant changes to healthcare regulation or pricing
What does Labcorp Holdings Inc. do?
Think of Labcorp as the engine room of modern medicine; when your GP orders a blood test or a biopsy, there is a good chance it ends up in one of their labs for analysis. Revenue comes from charging for these diagnostic tests and from helping pharmaceutical companies run complex clinical trials for new drugs. How they balance their core testing business against efforts to grow their drug-development services is the thing worth following.
On our factor screen it looks strongest on momentum and income, and weakest on quality.
- ✓Pays a dividend - about 0.9% a year
- ✓Growing - revenue up about 6% over the year
- Momentum screens high (79/100)
- Essential service that remains necessary regardless of the economy
- Strong position in both routine testing and complex drug research
- Solid earnings growth compared to the previous year
- Changes in government healthcare policy could impact pricing
- High competition from other large diagnostic laboratory chains
- Potential for data security breaches involving sensitive patient information
What do Labcorp Holdings Inc.'s numbers mean?
How much money does Labcorp Holdings Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Labcorp Holdings Inc. pay a dividend?
Yes - Labcorp Holdings Inc. currently pays a dividend of about 0.9% a year (the yearly payout as a share of the price). A dividend is a slice of profit handed to shareholders; the yield moves as the price moves, and a company can cut or stop it.
When does Labcorp Holdings Inc. report earnings, and how did recent quarters go?
Labcorp Holdings Inc. is next scheduled to report on about 2026-11-03 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $4.77 | $4.99 | Beat +5% |
| 2026-04-30 | $4.12 | $4.25 | Beat +3% |
| 2026-02-17 | $3.94 | $4.07 | Beat +3% |
| 2025-10-28 | $4.14 | $4.18 | Beat +1% |
| 2025-07-24 | $4.16 | $4.35 | Beat +4% |
| 2025-04-29 | $3.73 | $3.84 | Beat +3% |
Across the last 6 quarters here, Labcorp Holdings Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Labcorp Holdings Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Labcorp Holdings Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Essential service that remains necessary regardless of the economy
- Strong position in both routine testing and complex drug research
- Solid earnings growth compared to the previous year
- Relatively thin profit margins compared to some other healthcare sectors
- Modest dividend yield may not appeal to income-focused investors
- Heavy reliance on insurance and government reimbursement rates
- Changes in government healthcare policy could impact pricing
- High competition from other large diagnostic laboratory chains
- Potential for data security breaches involving sensitive patient information
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained drop in the number of medical tests ordered by doctors
- A major regulatory change that forces a significant cut to testing fees
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.